-
Mashup Score: 11
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 16
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
#FDA approves #Tirzepatide injection, the first GIP and #GLP1RA in #T2D #Diabetes #CVR @DLBHATTMD ☀️ https://t.co/gyyVfqUZHC
-
-
Mashup Score: 0FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company - 3 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp
-
-
Mashup Score: 1Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 | Eli Lilly and Company - 3 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
“tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1” I have a new love 😂😂 https://t.co/wNoe3JDMzH
-
More options for weight loss: Participants taking #tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint https://t.co/k05YzcnnZa
-
-
Mashup Score: 0Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis | Eli Lilly and Company - 3 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Latest Headlines, RheumatologyTweet-
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl
-
-
Mashup Score: 6
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited for the ESMO virtual plenary tomorrow with the updated monarchE presentation! Incredible for our HR+ patients! @myESMO @LillyPad https://t.co/TFJcly17kX
-
-
Mashup Score: 4FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps | Eli Lilly and Company - 3 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Endocrinology, Latest HeadlinesTweet-
RT @DrNBereolos: Big news in diabetes, Lyumjevr approved for use in insulin pumps. @ADCESdiabetes https://t.co/nqo4UhqlGV
-
-
Mashup Score: 13
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
Press release for empagliflozin for #HFpEF: met their primary endpoint! Look forward to seeing all the data! @hvanspall @AndrewJSauer @mpsotka @DrNasrien @JJheart_doc @mvaduganathan @SusanJosephMD @stormigale @UCSF_CVfellows @UCSFIMChiefs https://t.co/9IWaUmay0E
-
-
Mashup Score: 3
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
Great News in CV Medicine Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved EF https://t.co/qFwkDjgEiH @ErinMichos @MDedgeCardio @DLBHATTMD @EkateriniL @ShelleyZieroth @NMHheartdoc https://t.co/P8kaQFJfHB
-
-
Mashup Score: 2
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
Excited to see publication... but I do wonder, should we be getting "pre-release" company reports? @drjohnm https://t.co/FtNhe27Naj
-
BEBTELOVIMAB: Evusheld is a dual monoclonal antibody that protects those who are profoundly immunocompromised for 6 months but bebtelovimab is a treatment antibody & still works against BA4/BA5; please see pinned tweet for this tools among others for COVID https://t.co/a8VsN0kbK6